Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Postoperative Analgesia After Total Knee Arthroplasty

24 mai 2026 mis à jour par: Ayça Taş Tuna, Sakarya University

Effect of Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion on Postoperative Analgesia and Quality of Recovery After Total Knee Arthroplasty: A Prospective Randomized Double-Blind Controlled Trial

The goal of this clinical trial is to compare two different epidural analgesia delivery methods for pain control after total knee arthroplasty in adults undergoing elective surgery. The study will evaluate whether programmed intermittent epidural bolus (PIEB) provides better postoperative analgesia and recovery outcomes than continuous epidural infusion (CEI).

The main questions it aims to answer are:

Does PIEB reduce total epidural local anesthetic consumption during the first 24 postoperative hours compared with CEI? Does PIEB improve postoperative pain control and quality of recovery? Are there differences between the two methods regarding motor block, rescue analgesic requirement, patient-controlled epidural analgesia use, and adverse effects?

Researchers will compare PIEB plus patient-controlled epidural analgesia (PCEA) with CEI plus PCEA in patients undergoing total knee arthroplasty.

Participants will:

Receive combined spinal-epidural anesthesia during surgery Receive postoperative epidural analgesia using either PIEB or CEI Be evaluated for pain scores, motor block, recovery quality, epidural local anesthetic consumption, rescue analgesic requirement, and adverse events during the first 24 postoperative hours

Aperçu de l'étude

Description détaillée

Total knee arthroplasty (TKA) is one of the most commonly performed orthopedic procedures and is associated with significant postoperative pain. Inadequate pain control after TKA may delay mobilization, prolong hospitalization, impair rehabilitation, and negatively affect patient satisfaction and recovery quality. Therefore, optimizing postoperative analgesia while minimizing opioid consumption and preserving motor function is an important component of enhanced recovery after surgery (ERAS) protocols.

Epidural analgesia has been widely used for postoperative pain management for decades. Conventional continuous epidural infusion (CEI) provides stable delivery of local anesthetic but may be associated with uneven epidural spread, higher local anesthetic consumption, and increased motor blockade in some patients.

Programmed intermittent epidural bolus (PIEB) is an alternative epidural drug delivery technique in which local anesthetic is administered automatically at predefined intervals as intermittent boluses rather than as a continuous infusion. Due to the higher injection pressure and intermittent delivery pattern, PIEB may improve epidural spread and analgesic quality while reducing total local anesthetic requirements and motor block. Although PIEB has been extensively investigated in obstetric analgesia, evidence regarding its use in major orthopedic surgery remains limited.

This prospective, randomized, double-blind, parallel-group clinical trial aims to compare PIEB plus patient-controlled epidural analgesia (PCEA) with CEI plus PCEA in patients undergoing elective primary total knee arthroplasty under combined spinal-epidural anesthesia.

A total of 90 participants will be enrolled and randomized in a 1:1 ratio into two groups:

  • PIEB + PCEA group
  • CEI + PCEA group

Randomization will be performed using a computer-generated randomization sequence with allocation concealment through sequentially numbered opaque sealed envelopes.

All participants will receive standardized combined spinal-epidural anesthesia. Epidural catheter placement will be performed at the L2-L3 interspace using the needle-through-needle technique. Spinal anesthesia will be achieved with 12.5 mg hyperbaric bupivacaine administered intrathecally.

Postoperatively, all participants will receive epidural analgesia using the same epidural solution consisting of 0.1% bupivacaine diluted in normal saline.

In the PIEB group, epidural analgesia will be delivered as programmed intermittent epidural boluses of 6 mL every 60 minutes combined with patient-controlled epidural boluses of 6 mL with a 30-minute lockout interval.

In the CEI group, epidural analgesia will be delivered as continuous epidural infusion at 6 mL/hour combined with patient-controlled epidural boluses of 6 mL with a 30-minute lockout interval.

All participants will additionally receive standardized multimodal analgesia with scheduled paracetamol administration. Intravenous tramadol will be used as rescue analgesia when the visual analog scale (VAS) pain score is 4 or greater.

The primary outcome measure is total epidural local anesthetic consumption during the first 24 postoperative hours.

Secondary outcome measures include:

  • Quality of recovery assessed using the QoR-15 questionnaire
  • Motor block assessed with the modified Bromage scale
  • Number of patient-controlled epidural bolus demands and delivered boluses
  • Rescue analgesic consumption
  • Resting and movement-related VAS pain scores

Pain scores will be assessed at postoperative 2, 4, 8, 12, and 24 hours. QoR-15 will be evaluated preoperatively and at postoperative 24 hours.

The study will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent will be obtained from all participants before enrollment.

Type d'étude

Interventionnel

Inscription (Estimé)

90

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Adapazari
      • Sakarya, Adapazari, Turquie (Türkiye), 54000
        • Sakarya University Training and Research Hospital, Department of Anesthesiology and Reanimation
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Adults aged 18 to 80 years
  • American Society of Anesthesiologists (ASA) physical status I-III
  • Scheduled for elective primary total knee arthroplasty
  • Eligible for combined spinal-epidural anesthesia and postoperative epidural analgesia
  • Able to understand and use patient-controlled epidural analgesia
  • Provided written informed consent

Exclusion Criteria:

  • Refusal to participate in the study
  • Known allergy or hypersensitivity to study medications
  • Body mass index (BMI) ≥ 40 kg/m²
  • Body weight < 40 kg
  • Severe cardiac disease, including symptomatic arrhythmia or advanced conduction abnormalities
  • Coagulopathy (INR > 1.5 or platelet count < 100,000/mm³)
  • Pregnancy or breastfeeding
  • Revision total knee arthroplasty or emergency surgery
  • Active infection at the site of regional anesthesia
  • Chronic opioid use or opioid dependence
  • Neurological disease or preexisting motor/sensory deficit in the lower extremities
  • ASA physical status IV or V
  • Requirement for intraoperative epidural local anesthetic supplementation due to inadequate spinal anesthesia

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: PIEB
Participants will receive postoperative epidural analgesia using programmed intermittent epidural bolus (PIEB) combined with patient-controlled epidural analgesia (PCEA). The epidural solution will consist of 0.1% bupivacaine. Automatic epidural boluses of 6 mL will be delivered every 60 minutes. Patient-controlled epidural boluses of 6 mL with a 30-minute lockout interval will also be available.
Postoperative epidural analgesia delivered as programmed intermittent epidural boluses using 0.1% bupivacaine. Automatic boluses of 6 mL will be administered every 60 minutes in combination with patient-controlled epidural analgesia boluses of 6 mL with a 30-minute lockout interval.
Autres noms:
  • PIEB
Comparateur actif: CEI
Participants will receive postoperative epidural analgesia using continuous epidural infusion (CEI) combined with patient-controlled epidural analgesia (PCEA). The epidural solution will consist of 0.1% bupivacaine. Continuous epidural infusion will be administered at a rate of 6 mL/hour. Patient-controlled epidural boluses of 6 mL with a 30-minute lockout interval will also be available.
Postoperative epidural analgesia delivered as continuous epidural infusion using 0.1% bupivacaine at a rate of 6 mL/hour in combination with patient-controlled epidural analgesia boluses of 6 mL with a 30-minute lockout interval.
Autres noms:
  • CEI

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Total epidural local anesthetic consumption during the first 24 postoperative hours
Délai: From initiation of postoperative epidural analgesia in the post-anesthesia care unit (PACU) to postoperative 24 hours
Total epidural local anesthetic consumption will be calculated as the sum of automatic epidural boluses and patient-controlled epidural analgesia boluses delivered during the first 24 postoperative hours. Total consumption will be recorded in milliliters (mL) using epidural pump records.
From initiation of postoperative epidural analgesia in the post-anesthesia care unit (PACU) to postoperative 24 hours

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Quality of recovery assessed with QoR-15
Délai: Preoperative baseline and postoperative 24 hours
Postoperative recovery quality will be evaluated using the Quality of Recovery-15 (QoR-15) questionnaire. The QoR-15 is a validated 15-item patient-reported outcome measure with total scores ranging from 0 to 150, where higher scores indicate better recovery.
Preoperative baseline and postoperative 24 hours
Number of patient-controlled epidural analgesia bolus demands and delivered boluses
Délai: During the first 24 postoperative hours
The total number of patient-controlled epidural analgesia (PCEA) bolus demands and successfully delivered boluses will be recorded using epidural pump data.
During the first 24 postoperative hours
Rescue analgesic consumption
Délai: During the first 24 postoperative hours
Rescue analgesic consumption will be assessed as the total amount of intravenous tramadol administered for breakthrough pain requiring rescue analgesia.
During the first 24 postoperative hours
Resting and movement-related pain scores assessed with VAS
Délai: Postoperative 2, 4, 8, 12, and 24 hours
Postoperative pain intensity at rest and during movement will be assessed using a 10-point visual analog scale (VAS), where 0 indicates no pain and 10 indicates the worst imaginable pain.
Postoperative 2, 4, 8, 12, and 24 hours
Motor block assessed with the modified Bromage scale
Délai: Postoperative 2 and 4 hours
Motor block severity will be evaluated using the modified Bromage scale, ranging from 0 to 3, where 0 indicates no motor block and 3 indicates complete motor block. Higher scores indicate greater motor blockade. Motor block presence will additionally be defined as a Bromage score of 1 or greater.
Postoperative 2 and 4 hours

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 juin 2026

Achèvement primaire (Estimé)

1 juin 2027

Achèvement de l'étude (Estimé)

1 décembre 2027

Dates d'inscription aux études

Première soumission

18 mai 2026

Première soumission répondant aux critères de contrôle qualité

18 mai 2026

Première publication (Réel)

22 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

28 mai 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

24 mai 2026

Dernière vérification

1 mai 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Description du régime IPD

Individual participant data (IPD) sharing has not yet been determined. De-identified data may be shared upon reasonable request following publication of the study results, subject to institutional and ethical considerations.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner